 SOUTH SAN FRANCISCO, Calif., June 09, 2021 GLOBE NEWSWIRE -- Assembly Biosciences, Inc. Nasdaq: ASMB, a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus HBV, today announced that three abstracts have been accepted for presentation during the International Liver CongressTM 2021, the Annual Meeting of the European Association for the Study of the Liver EASL taking place virtually June 23-26, 2021. During the meeting, data from Assembly Bios three core inhibitor programs, vebicorvir VBR, ABI-H2158 2158 and ABI-H3733 3733, will be featured in an oral presentation and two poster presentations. 